Tempus AI, Inc. (NASDAQ: TEM) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.44 | Insider Own | 16.41% | Shs Outstand | 175.20M | Perf Week | -1.59% |
| Market Cap | 10.74B | Forward P/E | - | EPS next Y | 0.04 | Insider Trans | -5.77% | Shs Float | 106.50M | Perf Month | 11.30% |
| Enterprise Value | 11.35B | PEG | - | EPS next Q | -0.07 | Inst Own | - | Short Float | 28.05% | Perf Quarter | 25.52% |
| Income | -254.00M | P/S | 7.50 | EPS this Y | 86.07% | Inst Trans | - | Short Ratio | 5.01 | Perf Half Y | 20.39% |
| Sales | 1.43B | P/B | 24.13 | EPS next Y | 122.03% | ROA | -10.75% | Short Interest | 29.87M | Perf YTD | 3.78% |
| Book/sh | 2.54 | P/C | 13.16 | EPS next 5Y | - | ROE | -54.70% | 52W High | 104.32 -41.26% | Perf Year | -23.61% |
| Cash/sh | 4.66 | P/FCF | - | EPS past 3/5Y | - | ROIC | -13.95% | 52W Low | 40.77 50.31% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 58.24% 46.58% | Gross Margin | 63.98% | Volatility | 6.45% 7.17% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 7.93 | EPS Y/Y TTM | 68.70% | Oper. Margin | -19.76% | ATR (14) | 4.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.16 | Sales Y/Y TTM | 106.49% | Profit Margin | -17.77% | RSI (14) | 51.83 | Recom | 2.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.30 | EPS Q/Q | 81.82% | SMA20 | -1.38% | Beta | 2.58 | Target Price | 68.22 |
| Payout | 0.00% | Debt/Eq | 2.68 | Sales Q/Q | 21.27% | SMA50 | 9.60% | Rel Volume | 1.03 | Prev Close | 64.29 |
| Employees | 3,800 | LT Debt/Eq | 2.68 | Earnings | Nov 03 | SMA200 | 8.73% | Avg Volume | 6.42M | Price | 61.28 |
| IPO Date | Jun 14, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 71.99% 0.74% | Net Debt/EBITDA | -9.29 | Volume | 6,587,610 | Change | -4.68% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Initiated | UBS | Neutral | $70 |
| Sep-08-26 | Initiated | Rothschild & Co Redburn | Neutral | $67 |
| Sep-02-26 | Initiated | Raymond James | $80 | |
| Sep-02-26 | Initiated | Cantor Fitzgerald | Overweight | $80 |
| Sep-01-26 | Upgrade | Piper Sandler | Neutral → Overweight | $56 → $76 |
| Aug-04-26 | Reiterated | Piper Sandler | Neutral | $105 → $56 |
| Aug-03-26 | Reiterated | Stifel Nicolaus | $60 → $50 | |
| Aug-03-26 | Reiterated | BTIG | Buy | $80 → $70 |
| Aug-03-26 | Reiterated | HC Wainwright & Co. | Buy | $64 → $56 |
| Jul-16-26 | Reiterated | Guggenheim | Buy | $95 → $65 |
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,431 | 1,272 | 693 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 515 | 474 | 312 | — | — | — | — | — | |
| Gross Profit | 916 | 798 | 381 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 819 | 715 | 755 | — | — | — | — | — | |
| Research and Development | 365 | 319 | 317 | — | — | — | — | — | |
| Other Operating Expense | 15 | 17 | 0 | — | — | — | — | — | |
| Operating Income | -283 | -253 | -691 | — | — | — | — | — | |
| Interest Expense | 54 | 70 | 54 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 79 | 26 | 39 | — | — | — | — | — | |
| Net Income Before Taxes | -260 | -297 | -706 | — | — | — | — | — | |
| Income Taxes | -6 | -52 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -254 | -245 | -706 | — | — | — | — | — | |
| Net Income From Continuing Operations | -254 | -245 | -706 | — | — | — | — | — | |
| Net Income | -254 | -245 | -706 | — | — | — | — | — | |
| EPS (Recurring) | -1.43 | -1.41 | -4.60 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.43 | -1.41 | -4.60 | — | — | — | — | — | |
| EPS (Diluted) | -1.44 | -1.41 | -4.60 | — | — | — | — | — | |
| EBITDA | -91 | -119 | -610 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.71 | 8.08 | 7.89 | — | — | — | — | — | |
| Gross Margin | 64.01 | 62.74 | 54.98 | — | — | — | — | — | |
| Operating Margin | -19.78 | -19.89 | -99.71 | — | — | — | — | — | |
| Net Margin | -17.75 | -19.26 | -101.88 | — | — | — | — | — | |
| Shares Outstanding | 180 | 174 | 162 | — | — | — | — | — | |
| Market Capitalization | 11,030 | 10,275 | 5,469 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Fukushima Ryan | CEO, Data | Sep 01 '26 | Sale | 62.71 | 30,846 | 1,934,244 | 16,574 | Sep 03 |
| Epstein David R | Director | Sep 01 '26 | Sale | 65.55 | 250 | 16,388 | 30,844 | Sep 03 |
| Doudna Jennifer A | Director | Sep 01 '26 | Sale | 65.55 | 676 | 44,312 | 25,266 | Sep 03 |
| West Nadja | Director | Aug 28 '26 | Sale | 69.00 | 3,000 | 207,000 | 31,981 | Sep 01 |
| LEFKOFSKY ERIC P | CEO and Chairman | Aug 25 '26 | Sale | 68.46 | 250,000 | 17,114,468 | 150,000 | Aug 27 |
| Schoenherr Thomas Edward | CEO, Diagnostics | Aug 21 '26 | Sale | 70.00 | 2,694 | 188,580 | 87,021 | Aug 25 |
| Fukushima Ryan | CEO, Data | Aug 21 '26 | Sale | 70.00 | 14,286 | 1,000,020 | 47,420 | Aug 25 |
| Schoenherr Thomas Edward | CEO, Diagnostics | Aug 19 '26 | Sale | 58.40 | 8,082 | 471,991 | 89,715 | Aug 20 |
| Rogers James William | Chief Financial Officer | Aug 19 '26 | Sale | 60.00 | 26,313 | 1,578,780 | 106,024 | Aug 20 |
| Polovin Andrew | EVP, Chief Legal Officer | Aug 19 '26 | Sale | 56.00 | 7,927 | 443,912 | 138,140 | Aug 20 |
| Bartolucci Ryan M | Chief Accounting Officer | Aug 18 '26 | Sale | 49.61 | 6,175 | 306,342 | 67,866 | Aug 20 |
| Rogers James William | Chief Financial Officer | Aug 18 '26 | Sale | 49.61 | 22,529 | 1,117,664 | 132,337 | Aug 20 |
| LEFKOFSKY ERIC P | CEO and Chairman | Aug 18 '26 | Sale | 49.61 | 132,591 | 6,577,840 | 2,098,130 | Aug 20 |
| Schoenherr Thomas Edward | CEO, Diagnostics | Aug 18 '26 | Sale | 49.61 | 9,232 | 458,000 | 97,797 | Aug 20 |
| Fukushima Ryan | CEO, Data | Aug 18 '26 | Sale | 49.61 | 41,095 | 2,038,723 | 562,463 | Aug 20 |